Premium
ABSENCE OF PHARMACOKINETIC INTERACTION OF OFATUMUMAB AND BENDAMUSTINE IN PATIENTS WITH INDOLENT B‐CELL NON‐HODGKIN'S LYMPHOMA (INHL)
Author(s) -
ForeroTorres A.,
Claud Chandler J.,
Iyer S.P.,
Kanate A.S.,
Izquierdo M.,
Hoever P.,
Duval V.,
Quinlan M.,
Madan S.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_183
Subject(s) - medicine , ofatumumab , cmax , bendamustine , rituximab , pharmacokinetics , dosing , refractory (planetary science) , gastroenterology , lymphoma , oncology , physics , astrobiology